United States

People: Pernix Therapeutics Holdings Inc (PTX.OQ)

PTX.OQ on NASDAQ Stock Exchange Global Market

19 Oct 2018
Change (% chg)

$-0.04 (-4.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Sedor, John 

Mr. John A. Sedor serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Sedor has served as a member of the Board since March 2014. Mr. Sedor has been Chairman and Chief Executive Officer of SEDOR Pharmaceuticals, LLC since 2014 and served as President and CEO and a director of Cangene Corporation, a fully integrated developer and manufacturer of immune therapeutics, from 2011 until its acquisition by Emergent Biosolutions in February 2014. Prior to that, from 2008 until 2011, Mr. Sedor served as Chief Executive Officer and President of CPEX Pharmaceuticals since its spin-off from Bentley in 2008 until its acquisition by Footstar. Mr. Sedor was President of Bentley from 2005 until the spin-off of CPEX. From 2001 to May 2005, he was President and CEO of Sandoz, Inc. (a division of Novartis AG) and prior to that served in a number of senior executive capacities with other healthcare companies.

Basic Compensation

Total Annual Compensation, USD 1,067,530
Restricted Stock Awards, USD 27,800
Long-Term Incentive Plans, USD --
All Other, USD 149,443
Fiscal Year Total, USD 1,244,780

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --